Bioengineered probiotics as a new hope for health and diseases: An overview of potential and prospects

Future Microbiology

Volumn 11, Issue 4, 2016, Pages 585-600

  Kumar, Manoj ^a   Yadav, Ashok Kumar ^a   Verma, Vinod ^b   Singh, Birbal ^c   Mal, Gorakh ^c   Nagpal, Ravinder ^d   Hemalatha, Rajkumar ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b UNIVERSITY OF ALLAHABAD   (India)

^c INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

bioengineering; biotherapeutics; gut microbiota; probiotics; recombinant

Indexed keywords

ANTIBIOTIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; PROBIOTIC AGENT;

ANTIBIOTIC THERAPY; ANTINEOPLASTIC ACTIVITY; BACILLUS CEREUS; BACILLUS SUBTILIS; BIOENGINEERING; CELL LINE; COGNITION; DRUG SAFETY; ESCHERICHIA COLI; GENOMICS; HUMAN; INTESTINE FLORA; KOMAGATAELLA PASTORIS; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII SUBSP. LACTIS; LACTOBACILLUS JEJUNI; LACTOBACILLUS JENSENII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS SAKEI; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; METABOLIC DISORDER; METAGENOMICS; MICROBIOME; NONHUMAN; NUTRITION; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES BOULARDII; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; STREPTOCOCCUS GORDONII; BACTERIUM; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; METABOLIC ENGINEERING; PROCEDURES; TRENDS;

BACTERIA; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; METABOLIC ENGINEERING; PROBIOTICS;

EID: 84966670918     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.16.4     Document Type: Review

References (112)

1. Eloe-Fadrosh EA, Rasko DA. The human microbiome: from symbiosis to pathogenesis. Annu. Rev. Med. 64, 145-163 (2013).
2. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat. Rev. Microbiol. 9, 279-290 (2011).
3. Goodrich JK, Waters JL, Poole AC et al. Human genetics shape the gut microbiome. Cell 159, 789-799 (2014).
4. Olle B. Medicines from microbiota. Nat. Biotechnol. 31, 309-315 (2013).
5. Homayouni A, Bastani P, Ziyadi S et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J. Low. Genit. Tract Dis. 18, 79-86 (2014).
6. Smits LP, Bouter KE, de Vos WM et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 145, 946-953 (2013).
7. Alcock J, Maley CC, Aktipis CA. Is eating behavior manipulated by the gastrointestinal microbiota? Evolutionary pressures and potential mechanisms. Bioessays 36, 940-949 (2014).
8. Bahey-El-Din M, Gahan CG. Lactococcuslactis-based vaccines: current status and future perspectives. Hum. Vaccin. 7, 106-109 (2011).
9. Takiishi T, Korf H, Van Belle TL et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Invest. 122, 1717-1725 (2012).
10. Gardlik R, Palffy R, Celec P. Recombinant probiotic therapy in experimental colitis in mice. Folia Biol. (Praha). 58, 238-245 (2012).
11. Pöhlmann C, Thomas M, Förster S et al. Improving health from the inside: use of engineered intestinal microorganisms as in situ cytokine delivery system. Bioengineered 4, 172-179 (2013).
12. Caluwaerts S, Vandenbroucke K, Steidler L et al. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 46, 564-570 (2010).
13. Chen Z, Guo L, Zhang Y et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J. Clin. Invest. 124, 3391-3406 (2014).
14. Del Carmen S, de Moreno de LeBlanc A, Martin R et al. Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. Appl. Environ. Microbiol. 80, 869-877 (2014).
15. Turnbaugh PJ, Ley RE, Mahowald MA et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
16. Kumar M, Nagpal R, Kumar R et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp. Diabetes Res. Article ID 902917(2012), 1-14 (2012).
17. Nagpal R, Kumar A, Kumar M et al. Probiotics, their health benefits and applications for developing healthier foods: a review. FEMS Microbiol. Lett. 334, 1-15 (2012).
18. Al-Nedawi K, Mian MF, Hossain N et al. Gut commensal microvesicles reproduce parent bacterial signals to host immune and enteric nervous systems. FASEB J. 29, 684-695 (2014).
19. Reid G, Brigidi P, Burton JP et al. Microbes central to human reproduction. Am. J. Reprod. Immunol. 73, 1-11 (2015).
20. Singh B, Gautam SK, Verma V et al. Metagenomics in animal gastrointestinal ecosystem: potential biotechnological prospects. Anaerobe 14, 138-144 (2008).
21. Human Microbiome Project Consortium (HMPC). Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214 (2012).
22. Aagaard K, Ma J, Antony KM et al. The placenta harbors a unique microbiome. Sci. Transl. Med. 6, 237ra65 (2014).
23. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65 (2010).
24. Louis P, Flint HJ. How our gut microbes influence our behaviour. J. Neuroendocrinol. 25, 517-518 (2013).
25. Kumar M, Nagpal R, Verma V et al. Probiotic metabolites as epigenetic targets in the prevention of colon cancer. Nutr. Rev. 71, 23-34 (2013a).
26. Kumar M, Hemalatha R, Kumar R et al. Epigenetics, probiotic metabolites and colon cancer prevention: an overview of progress, opportunities and challenges. Med. Epigenet. 1, 60-69 (2013).
27. Singh B, Mal G, Bharti D et al. Probiotics in female reproductive health: paradigms, prospects and challenges. Curr. Womens Health Rev. 9, 236-248 (2013).
28. Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352-1355. (2000).
29. Cambray G, Mutalik VK, Arkin AP. Toward rational design of bacterial genomes. Curr. Opin. Microbiol. 14, 624-630 (2011).
30. Fehér T, Burland V, Pósfai G. In the fast lane: large-scale bacterial genome engineering. J. Biotechnol. 160, 72-79 (2012).
31. Qin J, Wang X, Kong J et al. Construction of a food-grade cell surface display system for Lactobacillus casei. Microbiol Res. 169, 733-740 (2014).
32. LeBlanc JG, Aubry C, Cortes-Perez NG et al. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol. Lett. 344, 1-9 (2013).
33. Amalaradjou MA, Bhunia AK. Bioengineered probiotics, a strategic approach to control enteric infections. Bioengineered 4, 379-387 (2013).
34. Bermúdez-Humarán LG, Aubry C, Motta JP et al. Engineering lactococci and lactobacilli for human health. Curr. Opin. Microbiol. 16, 278-283 (2013).
35. DeGrandis S, Law H, Brunton J et al. Globotetraosyl ceramide is recognized by the pig edema disease toxin. J. Biol. Chem. 264, 12520-12525 (1989).
36. Van Huynegem K, Loos M, Steidler L. Immunomodulation by genetically engineered lactic acid bacteria. Front. Biosci. (Landmark Ed). 14, 4825-4835 (2009).
37. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut 63, 1513-1521 (2014).
38. Braat H, Rottiers P, Hommes DW et al. A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759 (2006).
39. Paton AW, Morona R, Paton JC. Bioengineered microbes in disease therapy. Trends Mol. Med. 18, 417-425 (2012).
40. Robert S, Gysemans C, Takiishi T et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 63, 2876-2887 (2014).
41. Eskdale J, Kube D, Tesch H et al. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 46, 120-128 (1997).
42. Huibregtse IL, Zaat SA, Kapsenberg ML et al. Genetically modified Lactococcus lactis for delivery of human Interleukin-10 to dendritic cells. Gastroenterol. Res. Pract. 2012, 639291 (2012).
43. von Ossowski I, Pietilä TE, Rintahaka J et al. Using recombinant lactococci as an approach to dissect the immunomodulating capacity of surface piliation in probiotic Lactobacillus rhamnosus GG. PLoS ONE 8, e64416 (2013).
44. Benbouziane B, Ribelles P, Aubry C et al. Development of a stress-inducible controlled expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J. Biotechnol. 168, 120-129 (2013).
45. Ai C, Zhang Q, Ren C et al. Genetically engineered Lactococcus lactis protect against house dust mite allergy in a BALB/c mouse model. PLoS ONE 9, e109461 (2014).
46. Porzio S, Bossù P, Ruggiero P et al. Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria. BMC Biotechnol. 4, 27. (2004).
47. Zhou Z, Gong S, Li X et al. Expression of Helicobacter pylori urease B on the surface of Bacillus subtilis spores. J. Med. Microbiol. 64(Pt 1), 104-110 (2015).
48. Duan F, March JC. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl Acad. Sci. USA 107, 11260-11264 (2010).
49. Liu X, Lagenaur LA, Lee PP et al. Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl. Environ. Microbiol. 74, 4626-4635 (2008).
50. Chang TL, Chang CH, Simpson DA et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl Acad. Sci. USA 100, 11672-11677 (2003).
51. Dey B, Lagenaur LA, Lusso P. Protein-based HIV-1 microbicides. Curr. HIV Res. 11, 576-594 (2013).
52. Liu X, Lagenaur LA, Simpson DA et al. Engineered vaginal Lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 50, 3250-3259 (2006).
53. Brichacek B, Lagenaur LA, Lee PP et al. In vivo evaluation of safety and toxicity of a Lactobacillus jensenii producing modified cyanovirin-N in a rhesus macaque vaginal challenge model. PLoS ONE 8(11), e78817 (2013).
54. Yamamoto HS, Xu Q, Fichorova RN. Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide. BMC Microbiol. 13, 4 (2013).
55. Hanson ML, Hixon JA, Li W et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146, 210-221.e13 (2014).
56. Gao G, Qiao JJ, Yang CH et al. Functional expression of mouse insulin-like growth factor-I with food-grade vector in Lactococcus lactis NZ9000. Lett. Appl. Microbiol. 54, 404-409 (2012).
57. Palffy R, Gardlik R, Behuliak M et al. Salmonella-mediated gene therapy in experimental colitis in mice. Exp. Biol. Med. (Maywood) 236, 177-183 (2011).
58. Ricci S, Macchia G, Ruggiero P et al. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol. 3, 15 (2003).
59. Voigt RG, Jensen CL, Fraley JK et al. Relationship between omega-3 long-chain polyunsaturated fatty acid status during early infancy and neurodevelopmental status at 1 year of age. J. Hum. Nutr. Diet 15, 111-120 (2000).
60. Das UN, Fams MD. Long-chain polyunsaturated fatty acids in the growth and development of the brain and memory. Nutrition 19, 62-65 (2003).
61. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34, 1249-1257 (2011).
62. Demaison L, Moreau D. Dietary n-3 polyunsaturated fatty acids and coronary heart disease-related mortality: a possible mechanism of action. Cell. Mol. Life Sci. 59, 463-477 (2002).
63. Von Schacky C. The role of omega-3 fatty acids in cardiovascular disease. Curr. Atheroscler. Rep. 5, 139-145 (2003).
64. Gong Y, Wan X, Jiang M et al. Metabolic engineering of microorganisms to produce omega-3 very long-chain polyunsaturated fatty acids. Prog. Lipid Res. 56C, 19-35 (2014).
65. Lin Y, Jain R, Yan Y. Microbial production of antioxidant food ingredients via metabolic engineering. Curr. Opin. Biotechnol. 26, 71-78 (2014).
66. Heap JT, Theys J, Ehsaan M et al. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. Oncotarget 5, 1761-1769 (2014).
67. Hoffman RM. Back to the future: are tumor-targeting bacteria the next-generation cancer therapy? Methods Mol. Biol. 1317, 239-260 (2015).
68. Hiroshima Y, Zhao M, Zhang Y et al. Tumor-targeting Salmonella typhimurium A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice. PLoS ONE 10, e0134324 (2015).
69. Panteli JT, Forkus BA, Van Dessel N et al. Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr. Biol. (Camb) 7, 42334 (2015).
70. Panteli JT, Forkus BA, Van Dessel N et al. Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr. Biol. (Camb) 7, 423-434 (2015).
71. Van Dessel N, Swofford CA, Forbes NS. Potent and tumor specific: arming bacteria with therapeutic proteins. Ther. Deliv. 6, 385-399 (2015).
72. Stritzker J, Weibel S, Seubert C et al. Enterobacterial tumor colonization in mice depends on bacterial metabolism and macrophages but is independent of chemotaxis and motility. Int. J. Med. Microbiol. 300, 449-456 (2010).
73. Stritzker J, Szalay AA. Single-agent combinatorial cancer therapy. Proc. Natl Acad. Sci. USA 110, 8325-8326 (2013).
74. Chang WW, Lee CH. Salmonella as an innovative therapeutic antitumor agent. Int. J. Mol. Sci. 15, 14546-14554 (2014).
75. Lee CH, Wu CL, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther. 12, 175-184 (2005).
76. Ong ZY, Wiradharma N, Yang YY. Strategies employed in the design and optimization of synthetic antimicrobial peptide amphiphiles with enhanced therapeutic potentials. Adv. Drug Deliv. Rev. 78C, 28-45 (2014).
77. Amaral AC, Silva ON, Mundim NC et al. Predicting antimicrobial peptides from eukaryotic genomes: in silico strategies to develop antibiotics. Peptides 37, 301-308 (2012).
78. Kaznessis YN. Multiscale models of antibiotic probiotics. Curr. Opin. Chem. Eng. 6, 18-24 (2014).
79. Andreu D, Torrent M. Prediction of bioactive peptides using artificial neural networks. Methods Mol. Biol. 1260, 101-118 (2015).
80. Reardon S. Microbiome therapy gains market traction. Nature 509, 269-270 (2014).
81. Dash S, Clarke G, Berk M et al. The gut microbiome and diet in psychiatry: focus on depression. Curr. Opin. Psychiatry 28, 1-6 (2015).
82. Forsythe P, Kunze WA, Bienenstock J. On communication between gut microbes and the brain. Curr. Opin. Gastroenterol. 28, 557-562 (2012).
83. Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart disease: a critical review. J. Am. Coll. Nutr. 20, 5-19 (2001).
84. Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: a review. J. Am. Diet. Assoc. 101, 229-238; quiz 239-241 (2001).
85. Aydin A, Ahmed K, Zaman I et al. Recurrent urinary tract infections in women. Int. Urogynecol. J. 26, 795-804 (2014).
86. Flegal KM, Carroll MD, Ogden CL et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303, 235-241 (2010).
87. Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr. Opin. Endocrinol. Diabetes Obes. 19, 93-96 (2012).
88. Yadav H, Lee JH, Lloyd J et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J. Biol. Chem. 288, 25088-25097. (2013).
89. Gomes AC, Bueno AA, de Souza RG et al. Gut microbiota, probiotics and diabetes. Nutr. J. 13, 60 (2014).
90. Chen SW, Zhong J, Huan LD. Expression of human insulin in lactic acid bacteria and its oral administration in non-obese diabetic mice. Wei Sheng Wu Xue Bao 47, 987-991 (2007).
91. Gérard P. Gut microbiota and obesity. Cell Mol. Life Sci.73, 147-162 (2016).
92. Ley RE. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023 (2006).
93. Khan MT, Nieuwdorp M, Bäckhed F. Microbial modulation of insulin sensitivity. Cell Metab. 20, 753-760 (2014).
94. Peterson CT, Sharma V, Elmén L et al. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin. Exp. Immunol. 179, 363-377 (2015).
95. Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol. Psychiatry 74, 720-726 (2013).
96. Moloney RD, Desbonnet L, Clarke G et al. The microbiome: stress, health and disease. Mamm. Genome 25, 49-74 (2014).
97. Howland RH. Can a bug in the gut act like a drug in the brain? J. Psychosoc. Nurs. Ment. Health Serv. 53, 22-24 (2015).
98. Forsythe P, Kunze WA, Bienenstock J. On communication between gut microbes and the brain. Curr. Opin. Gastroenterol. 28, 557-562 (2012).
99. Abramov V, Khlebnikov V, Kosarev I et al. Probiotic properties of Lactobacillus crispatus 2,029: homeostatic interaction with cervicovaginal epithelial cells and antagonistic activity to genitourinary pathogens. Probiotics Antimicrob. Proteins 6, 165-176 (2014).
100. Brotman RM, Shardell MD, Gajer P et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J. Infect. Dis. 210, 1723-1733 (2014).
101. Buve A, Jespers V, Crucitti T et al. The vaginal microbiota and susceptibility to HIV. AIDS 28, 2333-2344 (2014).
102. Borges S, Silva J, Teixeira P. The role of lactobacilli and probiotics in maintaining vaginal health. Arch. Gynecol. Obstet. 289, 479-489 (2014).
103. Vangelista L, Secchi M, Liu X et al. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrob. Agents Chemother. 54, 2994-3001 (2010).
104. Rao S, Hu S, McHugh L et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc. Natl Acad. Sci. USA. 102, 11993-11998 (2005).
105. Stadlbauer V. Immunosuppression and probiotics: are they effective and safe? Benef. Microbes6, 823-828 (2015).
106. Sanders ME, Akkermans LM, Haller D et al. Safety assessment of probiotics for human use. Gut Microbes 1, 164-185 (2010).
107. Broaders E, Gahan CG, Marchesi JR. Mobile genetic elements of the human gastrointestinal tract: potential for spread of antibiotic resistance genes. Gut Microbes 4, 271-280. (2013).
108. Wong A, Ngu DY, Dan LA et al. Detection of antibiotic resistance in probiotics of dietary supplements. Nutr. J. 14(14), 95 (2015).
109. Rosander A, Connolly E, Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl. Environ. Microbiol. 74, 6032-6040 (2008).
110. Piñero-Lambea C, Ruano-Gallego D, Fernández LÁ. Engineered bacteria as therapeutic agents. Curr. Opin. Biotechnol. 35, 94-102 (2015).
111. Rovner AJ, Haimovich AD, Katz SR et al. Recoded organisms engineered to depend on synthetic amino acids. Nature 518, 89-93 (2015).
112. Gallagher RR, Patel JR, Interiano AL et al. Multilayered genetic safeguards limit growth of microorganisms to defined environments. Nucleic Acids Res. 43, 1945-1954 (2015).